Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term specific use results survey of Trastuzumab BS in HER2-positive gastric cancer
jRCT2071230094Completed
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab in Gastric cancer (HER2-positive), sponsored by Nippon Kayaku Co., Ltd. Primary endpoints: Safety: Adverse events, Efficacy: Tumor reduction effect and 1 more. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
Gastric cancer (HER2-positive)
Beyond the preview
Go deeper on jRCT2071230094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230094.